Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer
Liangliang Bai,1,2 Pengfei Zhang,1,2 Kexun Zhou,1,2 Weiting Liao,1,2 Qiu Li1,2 1Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, People’s Republic of China; 2West China Biomedical Big Data Center, Sichuan University, Chengdu,...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-12-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/cost-effectiveness-analysis-of-first-line-cetuximab-plus-leucovorin-fl-peer-reviewed-article-CMAR |